125 related articles for article (PubMed ID: 17192694)
1. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells.
Yamazaki H; Suzuki M; Aoki T; Morikawa S; Maejima T; Sato F; Sawanobori K; Kitahara M; Kodama T; Saito Y
J Atheroscler Thromb; 2006 Dec; 13(6):295-307. PubMed ID: 17192694
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins.
Morikawa S; Murakami T; Yamazaki H; Izumi A; Saito Y; Hamakubo T; Kodama T
J Atheroscler Thromb; 2005; 12(3):121-31. PubMed ID: 16020911
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.
Schaefer WH; Lawrence JW; Loughlin AF; Stoffregen DA; Mixson LA; Dean DC; Raab CE; Yu NX; Lankas GR; Frederick CB
Toxicol Appl Pharmacol; 2004 Jan; 194(1):10-23. PubMed ID: 14728975
[TBL] [Abstract][Full Text] [Related]
4. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
Muraki A; Miyashita K; Mitsuishi M; Tamaki M; Tanaka K; Itoh H
J Appl Physiol (1985); 2012 Aug; 113(3):479-86. PubMed ID: 22653988
[TBL] [Abstract][Full Text] [Related]
5. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.
Nakahara K; Kuriyama M; Sonoda Y; Yoshidome H; Nakagawa H; Fujiyama J; Higuchi I; Osame M
Toxicol Appl Pharmacol; 1998 Sep; 152(1):99-106. PubMed ID: 9772205
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase.
Ohira M; Endo K; Saiki A; Miyashita Y; Terai K; Murano T; Watanabe F; Tatsuno I; Shirai K
Metabolism; 2012 Oct; 61(10):1452-60. PubMed ID: 22520230
[TBL] [Abstract][Full Text] [Related]
7. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
von Keutz E; Schlüter G
Am J Cardiol; 1998 Aug; 82(4B):11J-17J. PubMed ID: 9737641
[TBL] [Abstract][Full Text] [Related]
8. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin decreased coenzyme Q in the left ventricle and skeletal muscle but not in the brain and liver in L-NAME-induced hypertension.
Kucharská J; Gvozdjáková A; Simko F
Physiol Res; 2007; 56 Suppl 2():S49-S54. PubMed ID: 17824807
[TBL] [Abstract][Full Text] [Related]
10. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
[TBL] [Abstract][Full Text] [Related]
11. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone.
Johnson TE; Zhang X; Bleicher KB; Dysart G; Loughlin AF; Schaefer WH; Umbenhauer DR
Toxicol Appl Pharmacol; 2004 Nov; 200(3):237-50. PubMed ID: 15504460
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
[TBL] [Abstract][Full Text] [Related]
13. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment.
Duncan AJ; Hargreaves IP; Damian MS; Land JM; Heales SJ
Toxicol Mech Methods; 2009 Jan; 19(1):44-50. PubMed ID: 19778232
[TBL] [Abstract][Full Text] [Related]
14. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
Pierno S; De Luca A; Tricarico D; Roselli A; Natuzzi F; Ferrannini E; Laico M; Camerino DC
J Pharmacol Exp Ther; 1995 Dec; 275(3):1490-6. PubMed ID: 8531120
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
16. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy.
Sidaway J; Wang Y; Marsden AM; Orton TC; Westwood FR; Azuma CT; Scott RC
Xenobiotica; 2009 Jan; 39(1):90-8. PubMed ID: 19219751
[TBL] [Abstract][Full Text] [Related]
17. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats.
Itagaki M; Takaguri A; Kano S; Kaneta S; Ichihara K; Satoh K
J Pharmacol Sci; 2009 Jan; 109(1):94-101. PubMed ID: 19129682
[TBL] [Abstract][Full Text] [Related]
18. Statins with different lipophilic indices exert distinct effects on skeletal, cardiac and vascular smooth muscle.
Irwin JC; Fenning AS; Vella RK
Life Sci; 2020 Feb; 242():117225. PubMed ID: 31881229
[TBL] [Abstract][Full Text] [Related]
19. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
20. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins.
Wiesbauer F; Kaun C; Zorn G; Maurer G; Huber K; Wojta J
Br J Pharmacol; 2002 Jan; 135(1):284-92. PubMed ID: 11786505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
